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by Selkoe, 2001). In PD, the lesions are called Lewy
bodies, are found in the cytoplasm, and are composed
primarily of the protein -synuclein (reviewed by Goed-
ert, 2001). In HD, the lesions are observed as intranuclear





tein huntingtin (reviewed by Zoghbi and Orr, 2000). All
of the proteins found in the above-mentioned lesionsThe most conspicuous feature of many neurodegener-
share a propensity to form an ordered fibrillar structureative disorders, including Alzheimer’s, Parkinson’s,
called amyloid (reviewed by Rochet and Lansbury,and Huntington’s disease, is the occurrence of protein
2000). Amyloid formation is thought to arise from partialaggregates in ordered fibrillar structures known as
unfolding and exposure of hydrophobic surfaces thatamyloid found inside and outside of brain cells. The
are normally buried in the core of a folded protein, thusappearance of aggregates in diseased brains implies
increasing attractive forces among protein molecules.an underlying incapacity in the cellular machinery of
Mutations that increase the production of amyloid causemolecular chaperones that normally functions to pre-
rare, early-onset forms of AD and PD (reviewed by Goed-vent the accumulation of misfolded proteins. Here we
ert, 2001; Selkoe, 2001). In HD, the length of the polyglu-review recent studies that have revealed a critical role
tamine (polyQ) expansion in huntingtin correlates di-for molecular chaperones in several neurodegenera-
rectly with kinetics of amyloid formation and indirectlytive disorders.
with age of onset and severity of the disease (reviewed
by Zoghbi and Orr, 2000). For AD, PD, and HD, theNeurodegenerative Diseases, Brain Lesions,
precise relationship between deposition of amyloid andAmyloid, and Molecular Chaperones
initiation of pathogenesis has been the subject of in-Alzheimer’s disease (AD) and Parkinson’s disease (PD)
tense scrutiny.are the two most common neurodegenerative disorders,
An additional feature that AD, PD, and HD share inaffecting a combined 6 million people in the United
common is the presence of molecular chaperones andStates alone. AD is the most common senile dementia,
components of the ubiquitin-proteasome degradationwhere it is estimated 10% of people over the age of 65
system in the brain lesions characteristic of each dis-are afflicted, whereas PD is the most common move-
ease (reviewed by Clark and Muchowski, 2000; Shermanment disorder, affecting 1%–2% of this same population
and Goldberg, 2001). All cells and organelles possessgroup. In AD and PD, the vast majority of cases are
a machinery of molecular chaperones whose functionidiopathic. In contrast, Huntington’s disease (HD) is a
is to mediate the proper folding of other proteins andless common neurodegenerative disorder that affects
to insure that these proteins maintain their native confor-at least 1 in 10,000 people in the general population.
mations during conditions of stress (reviewed by HartlThe mutation that causes HD is an expansion of CAG
and Hayer-Hartl, 2002). In addition to their functions inrepeats (encoding polyglutamine) in the gene huntingtin.
co- and posttranslational folding, chaperones are re-The mutation is inherited in an autosomal dominant
quired for the translocation of many proteins acrossmanner, and the same mutational mechanism is respon-
cellular membranes, are involved in macromolecular as-sible for a growing number of less common neurodegen-
sembly and disassembly, and facilitate the transfer oferative disorders that include the spinocerebellar atax-
misfolded proteins to the proteasome for degradation.ias (SCAs). AD, PD, and HD each display characteristic
Many chaperones are also components of signal trans-patterns of neuronal cell loss and behavioral pheno-
duction cascades that mediate transcriptional re-types. In AD, cell loss is most prominent in the neocortex
sponses to stress, including those that lead to the sup-and hippocampus, and is accompanied by memory loss,
pression of apoptosis. Chaperones function by binding
dementia, and impairment in other forms of cognition
transiently to exposed hydrophobic surfaces in target
and behavior. PD is characterized by a loss of dopamin-
proteins in a manner that is regulated by ATP-induced
ergic neurons in the substantia nigra and is accompa- conformational changes that occur in their substrate
nied by muscle rigidity, bradykinesia, and resting tremor. binding domains. Chaperones function to insure that
In HD, cells in the striatum and cortex are most affected, exposed hydrophobic surfaces are shielded from aber-
resulting in progressive chorea, rigidity, and dementia. rant interactions with other nearby proteins and folding
What then do these apparently disparate neurodegen- intermediates in the concentrated milieu of the cell. A
erative diseases have in common? One histological fea- defining feature of all chaperones is their predilection
ture they share is the occurrence of lesions in brains, for binding to folding and misfolding intermediates.
consisting of an intra- or extracellular accumulation of Molecular Chaperones Suppress
misfolded, aggregated, and ubiquitinated proteins that Neurodegeneration in Fly and Mouse Models
are intimately associated with neurodegeneration. The of Polyglutamine Diseases
lesions observed in AD are intracellular neurofibrillary Since 1998, approximately 15 publications have re-
tangles that contain the protein Tau and extracellular ported the effects of overexpression of chaperones in
plaques that contain -amyloid (A) peptides (reviewed cellular models of polyQ aggregation and toxicity. De-
spite the various polyQ proteins and cell types used in
these studies, in general these papers reported similar1Correspondence: mucho@u.washington.edu
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results, showing that members of the Hsp70 and Hsp40 disorders, whether or not their overexpression could
families of chaperones suppress the aggregation and have a beneficial effect in a major disorder of the nervous
toxicity of polyQ-containing proteins (reviewed by Sher- system (i.e., AD or PD) was an unanswered question,
man and Goldberg, 2001). until recently. Bonini and colleagues asked if overex-
The most compelling data that supports a critical role pression of Hsp70 could affect neuropathology in a Dro-
for chaperones in protein misfolding diseases comes sophila model of PD. In this model, overexpression of
from recent in vivo studies in fruit fly and mouse models -synuclein driven by the 3,4-dihydroxyphenylalanine
of neurodegenerative disorders (Auluck et al., 2002; (DOPA) decarboxylase gene promoter leads to a selec-
Cummings et al., 2001; Fernandez-Funez et al., 2000; tive and progressive loss of dopaminergic neurons. In-
Kazemi-Esfarjani and Benzer, 2000; Warrick et al., 1999). deed, not only could Hsp70 overexpression suppress
In the first study, a Drosophila melanogaster model of the loss of dopaminergic neurons, but expression of a
Machado-Joseph disease (also known as SCA3) was dominant-negative Hsp70 exacerbated the neurode-
used to characterize the effects of overexpression of generative phenotype significantly (Auluck et al., 2002).
human Hsp70. Expression of the expanded polyQ pro- Interestingly, expression of the dominant-negative Hsp70
tein was driven by an eye-specific promoter, causing caused some dopaminergic neuron loss even in the ab-
severe degeneration of external eye structures and sence of -synuclein, suggesting a role for endogenous
eventual loss of the retina (Warrick et al., 1999). Overex- Hsp70 in neuronal survival. The authors also showed
pression of human Hsp70 completely suppressed the that a small percentage of Lewy Bodies in postmortem
external eye defects mediated by the expression of ex- PD brain tissue react with antibodies raised against
panded polyQ in these flies, and partially restored retinal Hsp70 and Hsp40, suggesting that these chaperones
structure. In a second set of experiments, expression may play a role in the human disease. These results
of the expanded polyQ protein under the control of a expand the protective role of chaperones to a major
neuron-specific promoter caused widespread neurode- neurodegenerative disease, and are intriguing because
generation and also decreased fly viability. Overexpres- PD may have a completely different molecular mecha-
sion of human Hsp70 in these flies suppressed neurode- nism than HD and the polyQ diseases.
generation and prolonged lifespan by 2-fold. Perhaps Mechanisms of Chaperone Protection in Models
most intriguing, expression of the expanded polyQ pro-
of Neurodegenerative Diseases
tein in a fly line bearing a dominant-negative Drosophila
If chaperones suppress neurodegenerative phenotypesHsp70 augmented the severity and kinetics of neurode-
in models of protein misfolding disorders in vivo butgeneration, suggesting that under normal conditions the
have no discernible effect on aggregation of the disease-endogenous fly Hsp70 may partially mitigate the toxic
causing proteins, what then is the mechanism of protec-effects of the expanded polyQ protein (Warrick et al.,
tion? One clue may come from in vitro studies that exam-1999). Paradoxically, at the level of light microscopy,
ined the physical and biochemical effects of chaperonesthere appeared to be no effect on aggregate formation
on fibril formation by a truncated version of the hunting-by the polyQ protein.
tin protein (Muchowski et al., 2000). In our studies, theTwo subsequent studies took advantage of genetic
Hsp70/Hsp40 chaperone system inhibited in an ATP-tools available in Drosophila to perform screens for mod-
dependent manner the self-assembly of polyQ proteinsifiers of polyQ-induced toxicity. In the first study, two
into amyloid-like fibrils. Electron microscopy demon-genes were isolated that dramatically reduced polyQ
strated that the chaperones caused the formation oftoxicity. The first gene encoded a Drosophila homolog
amorphous (as opposed to protofibrillar or fibrillar), de-of human Hsp40/HDJ1 (dHDJ1), a co-chaperone for
tergent-soluble aggregates. The chaperones were mostHsp70 in vivo, and the second gene encoded a Drosoph-
active in preventing fibrillization when added during theila homolog of human tetratricopeptide repeat protein 2
lag phase of the polymerization reaction, indicating that(Kazemi-Esfarjani and Benzer, 2000). Interestingly, both
the molecular species with which they preferentially in-proteins contain a conserved J domain that is known
teract exists in an intermediate, pre-fibrillar state. Hsp70to stimulate the ATPase activity of Hsp70 and may func-
alone had only a modest effect on inhibiting fibril forma-tion in vivo to help target folding intermediates to Hsp70.
tion, but in the presence of its co-chaperone Hsp40,In an independent study, dHDJ1 was also isolated as a
complete suppression of fibril formation was observed.suppressor of polyQ-mediated toxicity induced by the
Consistent with in vitro results, overexpression of Hsp70expression of full-length human SCA1 in fruit flies (Fer-
or Hsp40 in yeast and mammalian cell models of polyQnandez-Funez et al., 2000).
aggregation inhibited the formation of large, detergent-The remarkable finding that overexpression of chaper-
insoluble inclusion bodies, resulting instead in the accu-ones can suppress neurodegeneration in vivo has been
mulation of detergent-soluble inclusions. Not surpris-extended to mammals, where it was shown that increas-
ingly, fibrillar aggregates could not be detected at theing levels of Hsp70 in a mouse model of SCA1 mitigates
ultrastructural level by electron microscopy under theseneurodegeneration (Cummings et al., 2001). Importantly,
cellular conditions (Sittler et al., 2001). The synergisticoverexpression of Hsp70 not only reduced pathological
effects of chaperones to increase polyQ solubility werechanges in SCA1 mice, but also behavioral phenotypes.
confirmed in an in vivo model of polyQ-induced neuro-However, as in the fly models, there appeared to be no
degeneration in Drosophila (Chan et al., 2000). In thischanges in aggregate formation by SCA1 as judged by
model, overexpression of Hsp70 and/or Hsp40 en-light microscopy.
hanced the solubility of polyQ proteins concomitant withMolecular Chaperones Suppress
protection against neurodegeneration, but without hav-Neurodegeneration in a Fly Model
ing any effect on the morphology of polyQ aggregates asfor Parkinson’s Disease
judged by light microscopy. These studies collectivelyWhile accumulating evidence indicates a neuroprotec-
tive role for chaperones in HD and other polyQ-mediated underscore the importance of analyzing aggregation in
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chaperones in other cellular pathways such as in the
suppression of signaling cascades that lead to apopto-
sis, or in protection against defects in synaptic trans-
mission, are some examples of areas that are being
investigated actively that may help explain chaperone
suppression of neurotoxicity. Clearly, the effects of
chaperones in multiple cellular pathways will have to be
deciphered in order to understand which of these effects




Recent studies support the hypothesis that pre-fibrillar
intermediates (protofibrils), and not mature amyloid fi-
brils, may be the key toxic species in AD, PD, and HD. In
vitro studies with two mutants of -synuclein associated
Figure 1. A Model for Molecular Chaperone Suppression of Neuro- with inherited forms of PD showed that both mutations
toxicity cause an acceleration of oligomerization, and not fibril-
Molecular chaperones may suppress neurotoxicity of amyloid-form- lization (Conway et al., 2000). In a related study that
ing proteins by preventing their conversion between native confor- supports an important role for protofibrils, oxidation-
mations and toxic conformations (A), by preventing the formation of induced adduct formation between -synuclein and ca-
pre-fibrillar intermediates (B), by preventing the conversion between
telcholamines, including dopamine, caused an accumu-pre-fibrillar intermediates and mature fibrils (C), and/or by facilitating
lation of protofibrils, and this process was reversed bythe conversion of toxic intermediates into nontoxic amorphous ag-
addition of anti-oxidants (Conway et al., 2001). Consis-gregates (D). Irrespective of the neuroprotective mechanisms they
invoke, an excess of chaperones in cells leads to the formation of tent with a toxic role for protofibrils in AD, small oligo-
detergent-soluble and amorphous aggregates (D) that are degraded mers of A potently inhibited hippocampal long-term
more readily by the proteolytic machinery, thus preventing aberrant potentiation in vivo, while fibrillar and monomeric forms
protein interactions that would otherwise lead to a cascade of events had no effect (Walsh et al., 2002). In an independentthat culminate in neurodegeneration.
study, when two proteins not known to be involved in
disease were incubated under conditions where they
formed amyloid fibrils, only the pre-fibrillar intermedi-disease models by methods other than conventional
ates and not the mature fibrils caused cytotoxicity (Buc-light microscopy, which poorly detects morphological
ciantini et al., 2002). Evidence for a toxic role for pre-changes in protein aggregates and is unable to detect
fibrillar intermediates in HD comes from our study whichunderlying physical and biochemical changes in the dis-
showed that disruption of the microtubule cytoskeletonease-causing proteins that are likely to be more perti-
in cell models for huntingtin aggregation unmasks a
nent to neurotoxicity. This situation is reminiscent of
glutamine length-dependent toxicity under conditions
studies in AD which have shown that levels of soluble
where the huntingtin protein exists in a completely nonfi-
forms of A more closely correlate with pathology than
brillar state (Muchowski et al., 2002). The results from
levels of insoluble, fibrillar forms present in amyloid
this study are consistent with an accumulation of data
plaques (Walsh et al., 2002; reviewed by Selkoe, 2001). that dissociates aggregation of polyQ-containing pro-
These toxic soluble forms (see below) are presumably teins (judged at the level of light microscopy) from toxic-
distinct from the “amorphous,” detergent-soluble forms ity (reviewed by Zoghbi and Orr, 2000). In light of results
that one would predict might be increased by chaperone that highlight the toxic nature of protofibrils, and based
treatment in models of AD. on the known affinity of chaperones for folding interme-
Chaperones are one of the best examples of multi- diates, it is tempting to speculate that chaperones pro-
functional proteins, and their protection against neuro- tect against neurodegeneration in animal models by act-
degeneration may result from one or more of their activi- ing at the level of protofibrils. It might be argued that
ties in cells, perhaps in addition to their ability to inhibit by binding to protofibrils, chaperones induce a confor-
fibril formation directly. In one recent study, the Hsp70/ mational change that leads to the generation of amor-
Hsp40 chaperone system was shown not only to en- phous, nontoxic aggregates, which at the same time
hance the solubility of expanded polyQ proteins, but to also decreases the cellular concentration of mature am-
also increase the degradation of these proteins through yloid fibrils.
the 26S proteasome (Bailey et al., 2002). The increase Future Directions
in polyQ solubility was accompanied by a 40% decrease While it is becoming clear that chaperones can have a
in the half-life of the expanded polyQ proteins. This profound influence on solubility, aggregation, fibril for-
important result indicates that an excess of chaperone mation, and toxicity of proteins that misfold and cause
capacity in the cell can shift the equilibrium between neurodegenerative disorders, many issues remain to be
amorphous (detergent-soluble) and fibrillar (detergent- examined. The disease-causing proteins associated
insoluble) aggregates such that the cell’s proteolytic with AD, PD, and HD can apparently misfold into multiple
machinery can more efficiently turn over the toxic polyQ toxic conformations and pre-fibrillar intermediates with
proteins. Nevertheless, the mechanism chaperones use different morphologies. However, the structural nature
to facilitate clearance of misfolded proteins by the pro- and, just as importantly, downstream targets of these
teasome remains to be elucidated, and may indicate a intermediates remain uncharacterized and will need to
be elucidated if they are to be pursued as drug targets.useful target for pharmacological intervention. A role for
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Chaperones may protect against neurodegenerative progression and severity in patients with neurodegener-
ative disorders.disorders in animal models by acting at one or more
steps in the pathway of fibril formation (Figure 1). Chap- In summary, recent studies suggest that chaperones
may play a critical role in neurodegeneration and aging,erones may convert toxic conformations of misfolded
proteins to nontoxic forms that can be tolerated by cells, and this class of proteins holds much promise as a
therapeutic target for the treatment of neurodegenera-although direct biophysical evidence for this hypothesis
is lacking. Chaperones may also prevent the formation tive disorders. While the identification of small mole-
cules that can enhance chaperone expression or activi-of toxic pre-fibrillar intermediates, or accelerate their
conversion to nontoxic amorphous aggregates that can ties in brain cells may seem like a daunting task, it is
worthy to note that a small molecule antagonist of thebe turned over more easily by the proteolytic machinery.
Although evidence indicates that chaperones act on chaperone Hsp90 is currently in clinical trials for the
treatment of recurrent, refractory breast cancer (Baga-pre-fibrillar intermediates and not mature fibrils (Mu-
chowski et al., 2000), the molecular basis of these inter- tell et al., 2001).
actions is not known and should be resolved.
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